Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

Cancer

Volumn 110, Issue 3, 2007, Pages 499-508

  Risebrough, Nancy A ^a   Verma, Shailendra ^b   Trudeau, Maureen ^a   Mittmann, Nicole ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant therapy; Cost effectiveness; Cost utility; Exemestane; Primary breast cancer; Tamoxifen

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRACTURE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THROMBOEMBOLISM;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; SEER PROGRAM; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAMOXIFEN;

EID: 34547102735     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22824     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(suppl 7):vii10-vii14.
3. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
4. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
5. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-462.
6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
7. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-2139.
8. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics. 2006;24:215-232.
9. Eisen A, Trudeau M, Shelley W, Sinclair S,Breast Cancer Disease Site Group. The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer. On Cancer Care Ontario website [updated 2005]. Available at: http://www.cancer-care.on.ca/pdf/pebcl- 18s.pdf. Accessed January 31, 2007.
10. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. Available at: www.cadth.ca. Accessed January 31, 2007.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
12. Baxter N, Goel V, Semple JL. Utilization and regional variation of breast reconstruction in Canada. Plast Reconstr Surg. 2005;115:338-339.
13. Pfizer Canada Inc. Aromasin product monograph. 2006 Apr 26. Report No.: 097618. Pfizer Canada, 2006.
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
15. National Cancer Institute. Surveillance epidemiology and end results. Available at: www.seer.cancer.gov. Accessed January 31, 2007.
16. Sorensen SV, Brown R, Benedict A, Flood E, Revicki D. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health. 2004;7:641-642.
17. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, Der Maas PJ. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49:538-544.
18. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Sum 1983;38:445-455.
19. Statistics Canada. Canadian consumer price index, health care component. Ottawa: Statistics Canada; 2004.
20. Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer. 2003;11:728-734.
21. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36:724-735.
22. Trudeau M, Charbonneau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6:886-898.
23. Will BE Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK. Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada, and their associated costs. Br J Cancer. 1999;79:1428-1436.
24. Canadian Institute for Health Information. Cost per hospitalization by selected ICD-9-CM diagnoses related to breast cancer and fractures (fiscal year 2000/2001). Available at: http://secure.cihi.ca/cihiweb/dispFage.jsp?cw_page= coding-class_icd9cm_e. Accessed January 31, 2007.
25. Ontario Ministry of Health and Long-Term Care. OHIP schedule of benefits for laboratory services. Available at: http://www.health.gov.on.ca/english/ providers/program/ ohip/sob/lab/lab_mn.html. Accessed January 31, 2007.
26. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act. Available at: http://www.health.gov.on.ca/eng-lish/providers/program/ohip/sob/physserv/ physserv_mn. html. Accessed January 31, 2007.
27. Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index no. 39. Available at: http://www.health.gov.on. ca/english/provi-ders/program/drugs/edition_39.html. Accessed January 31, 2007.
28. Boucher M, Rodger M, Johnson JA, Tierney M. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost-minimization analysis. Pharmacotherapy. 2003;23:301-309.
29. Mittmann N, Brown A, Seung SJ, et al. Economic evaluation of drug eluting stents. Report No. 53. Ottawa, Ontario, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2005.
30. Brown JE, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 suppl):S1-S34.
31. Genest J, Frohlich J, Fodor G, McFherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169:921-924.
32. Rodger MA, Gagne-Rodger C, Howley HE, Carrier M, Coyle D, Wells PS. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res. 2003;112:13-18.
33. Eichler HG, Kong SX, Gerth WC, Mavros E Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-528.
34. Delea TE, Karnon J, Smith R, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006;12:374-86.
35. Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101:37-49.
36. Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006;17:217-225.
37. National Institute for Health and Clinical Excellence. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Report No. 112. London, UK: National Institute of Clinical Excellence; 2006.
38. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006;14:917-927.
39. Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat. 2007;101:325-333. Epub 2006 Aug 2.
40. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101:1311-1322.
41. Duffy SR, Distler W. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial. Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2005.
42. Evans WK, Will BE, Berthelot JM, Wolfson MC. Estimating the cost of lung cancer-diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995;5:408-419.
43. Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2003;24:91-101.
44. Pinilla J. Cost minimization analysis of high-dose-rate versus low-dose-rate brachytherapy in endometrial cancer. Gynecology Tumor Group. Int J Radiat Oncol Biol Phys. 1998;42:87-90.